Percardia, Inc. Invited to Present at Prestigious Conference
Merrimack, NH, October 24, 2003 - Percardia, Inc., a venture funded medical device company focused on the development of novel therapies for the treatment of coronary artery disease ("CAD") has been invited to present at Medtech Insight's Ninth Investment In Innovation (In3) conference, being held in Boston, October 30-31, 2003. This two-day event will highlight emerging medical technologies and will draw an attendance of up to 300 senior executives from the investment community as well as major medical technology, biopharmaceutical, and biotechnical companies.
Percardia, Inc. is a venture funded medical device company focused on the development of novel therapies for the treatment of coronary artery disease ("CAD"). The company is developing a unique method for supplying blood to the coronary vessels that will solve many of the problems associated with coronary artery bypass graft ("CABG") surgery and percutaneous transluminal coronary angioplasty ("PTCA"). The company has raised $55 million to fund research, development, and clinical trials of its VCAB/VSTENT device. Nancy Briefs, Percardia's President & CEO, and her senior management team have over a century of combined experience developing and commercializing devices for cardiovascular medicine.
An estimated 298,000 patients in the US alone and 557,000 worldwide will undergo bypass surgery in 2004. Additionally 1,085,000 patients will undergo a minimally invasive revascularization procedure called PTCA. The Company's VSTENT Myocardial Implant1 introduces a "disruptive" therapy that will target both groups of patients. There is currently no equivalent product available.
A clinical evaluation of the VSTENT is currently taking place in Europe as part of the ADVANTAGE [Adjunctive Treatment with the VCAB/VSTENTTM Myocardial Implant System in Coronary Artery Bypass Graft (CABG) Patients] Study. Similar to traditional intra-coronary stents that are used to hold open blocked arteries, the VSTENT Myocardial Implant provides in situ scaffolding that establishes a direct channel to deliver oxygenated blood from the left ventricle of the heart to a targeted coronary vessel. The first generation implant is a balloon-deployable stainless steel stent, which consists of biomaterials that have a proven safety record of implantation into humans. The VSTENT Myocardial Implant is a Class III cardiovascular implant requiring Pre-Market Approval (PMA) in the United States and the CE Mark in the European Union (EU).
Additional information regarding the company and it's technology can be obtained at the company's website www.percardia.com.
1 VSTENT Myocardial Implant is a trademark of Percardia, Inc.